SCHEMBL20158639

SCHEMBL20158639

CCN1CCC(C)(NC(=O)C2CCN2C)CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.39
DRD2 P14416 2/20 0.37
CHRM1 P11229 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
EPHX1 P07099 3/20 0.35
EPHX2 P34913 2/20 0.35
HSD11B1 P28845 3/20 0.33
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
OPRM1 P35372 2/20 0.31
OPRD1 P41143 2/20 0.31
OPRK1 P41145 2/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21651941 0.84 RET (0.37) RETDRD2CHRM1EPHX2MAPT
SCHEMBL20069819 0.79 RET (0.35) RETDRD2CHRM1CYP3A4CYP2D6
SCHEMBL2604735 0.75 CYP3A4 (0.46) RETCHRM1HSD11B1CYP3A4CYP2D6
SCHEMBL16306650 0.74 DRD2 (0.46) DRD2SMN1; SMN2EPHX1EPHX2HSD11B1
SCHEMBL12733477 0.74 CYP3A4 (0.44) RETCHRM1SMN1; SMN2HSD11B1KDM4E
SCHEMBL22856999 0.73 DRD2 (0.46) RETDRD2CHRM1SMN1; SMN2EPHX1
SCHEMBL20147974 0.73 CYP2D6 (0.41) DRD2SMN1; SMN2EPHX1EPHX2HSD11B1
SCHEMBL20147337 0.71 CYP2D6 (0.40) RETCHRM1HSD11B1CYP3A4CYP2D6
SCHEMBL21651966 0.70 P2RX7 (0.41) RETDRD2SMN1; SMN2KDM4EMAPT
SCHEMBL20206011 0.70 RET (0.41) RETCHRM1SMN1; SMN2EPHX1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885DRD2 3425/4885CHRM1 2035/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885DRD2 3425/4885CHRM1 2035/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885DRD2 3425/4885CHRM1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.